tbuckley/cabot-search huggingface dataset:
The Liver of Dyspeptics; and particularly the Cirrhosis Produced by Auto-Intoxication of Gastro-Intestinal Origin.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute myelofibrosis terminating in acute lymphoblastic leukemia: Case report and review of the literature
Authors: Cherie H. Dunphy, Sarah Kitchen, Oscar Saravia, William S. Velasquez
Journal: American Journal of Hematology (1996)

Acute myelofibrosis (AMF), as defined by an acute panmyelopathy associated with marked megakaryocytic hyperplasia and marrow fibrosis, appears to be a stem cell disorder. Even though it is most difficult to distinguish from various myeloproliferative and myelodysplastic disorders as well as acute myelogenous leukemia, it has rarely been reported to terminate as acute lymphoblastic leukemia (ALL). Only five cases have been reported in the literature; two from the pediatric literature and only three from the adult literature. Of the three adult cases, two were defined by light microscopy alone. Among the cases with follow-up (3/5), all died within 2 weeks to 2 months of diagnosis. We report an additional case in an adult; the ALL was defined by morphology, flow cytometric immunophenotyping, and cytogenetic analysis. The interval from diagnosis of AMF to ALL was 3 months. Our patient was treated with standard therapy for ALL, was in complete remission at last follow-up (3 months off maintenance therapy), and represents the only reported case who attained a complete remission. There are too few cases to determine the prognostic significance of termination of AMF in an acute leukemia of lymphoid origin vs. myeloid origin. © 1996 Wiley-Liss, Inc.
EHRLICH’S NEW REMEDY FOR SYPHILIS
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: David Healy
Journal: Psychotherapy and Psychosomatics (2004)

Letters| June 08 2004 Reply Subject Area: Psychiatry and Psychology David Healy David Healy North Wales Department of Psychological Medicine, Hergest Unit, Ysbyty Gwynedd, Bangor Gwynedd, UK Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (2004) 73 (4): 262. https://doi.org/10.1159/000077749 Article history Published Online: June 08 2004 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation David Healy; Reply. Psychother Psychosom 1 August 2004; 73 (4): 262. https://doi.org/10.1159/000077749 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search This content is only available via PDF. 2004Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Article PDF first page preview Close Modal You do not currently have access to this content.
Lilac of Arnold Arboretum of Harvard University
Journal: JAMA Internal Medicine (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
Authors: T Poynard
Journal: Hepatology (1996)

The aims of this study were to evaluate the benefits of higher doses or of longer duration in comparison with a standard interferon regimen (3 MU three times per week for 6 months) in chronic hepatitis C, and to assess the efficacy of interferon in acute hepatitis C. Meta-analysis made use of the Peto et al. and the Der Simonian and Laird methods, with heterogeneity and sensitivity analyses. In chronic hepatitis, a total of 17 trials versus controls and of 16 trials comparing different interferon regimens were included. Standard regimen, 3 MU three times per week for 6 months, was associated with an increase of the complete alanine transaminase (ALT) response rate and sustained (ALT) response rate by 45% (95% confidence interval: 35% to 55%; P < .001) and 21% (13% to 28%; P < .001), respectively, with the natural course being less than 2% of spontaneous responses. There was a significant dose effect (6 vs. 3 MU three times per week) upon the sustained response rate at 12 months, with a mean 17% increase (7% to 28%; P < .001), but not at 6 months. There was a significant duration effect (12 vs. 6 months) upon the sustained response rate both at the dose of 3 MU with a mean of 16% (9% to 23%; P < .001), and at the dose of 6 MU three times per week with a mean of 20% (7% to 33%; P = .003). In acute hepatitis C, 3 months of interferon treatment showed significant efficacy versus controls (4 trials), upon the complete ALT response (69% vs. 29%; P < .001), the sustained response rate during the 12 months following treatment (53% vs. 32%; P = .02), and hepatitis C virus (HCV)-RNA clearance (41% vs. 4%; P < .001). The best efficacy/risk ratio was in favor of 3 MU three times per week for at least 12 months in patients with chronic hepatitis C who had never been treated with interferon. Patients with acute hepatitis should be treated with at least 3 MU three times per week for 3 months.
The Relationship Between Hospitalists and Primary Care Physicians
Authors: Mark J. Ault
Journal: Annals of Internal Medicine (2010)

Letters6 April 2010The Relationship Between Hospitalists and Primary Care PhysiciansMark J. Ault, MDMark J. Ault, MDFrom Cedars-Sinai Medical Center, Los Angeles, CA 90048.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-7-201004060-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:As an academic general internist of similar vintage as Beckman (1), I sympathize with his sense of loss of the “old days,” when the general internist was the utility player seeing patients in the office, following them through the emergency department and in and out of the intensive care unit, and discharging them back to the office. Admittedly, those days are gone, and no rearrangement of incentives is going to bring them back. Medicine and hospitals have gotten too complicated. However, a relatively simple incentive with a modest financial investment may help shore up a more patient-centered ...Reference1. Beckman H. Three degrees of separation. Ann Intern Med. 2009;151:890-1. [PMID: 20008765] LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Mark J. Ault, MDAffiliations: From Cedars-Sinai Medical Center, Los Angeles, CA 90048.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThree Degrees of Separation Howard Beckman The Relationship Between Hospitalists and Primary Care Physicians Michael D. Stillman The Relationship Between Hospitalists and Primary Care Physicians P. Dileep Kumar The Relationship Between Hospitalists and Primary Care Physicians Robert M. Wachter The Relationship Between Hospitalists and Primary Care Physicians Carl H. Reynolds , Balazs Zsenits , and Walter A. Polashenski Metrics Cited byVariation in Length of Stay and Outcomes among Hospitalized Patients Attributable to Hospitals and HospitalistsFrustrations With Hospitalist Care: Need to Improve Transitions and CommunicationThe Editors 6 April 2010Volume 152, Issue 7Page: 475KeywordsConflicts of interestHealth careHospital medicineHospitalistsInformation technologyIntensive care unitsMotivationPatients ePublished: 6 April 2010 Issue Published: 6 April 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Immunofluorescent skin test in systemic lupus erythematosus. Lack of relationship with renal disease
Authors: E. M. Caperton
Journal: JAMA (1972)

The results of immunofluorescent stains of skin biopsy specimens from 29 patients with systemic lupus erythematosus (SLE) were correlated with the presence, type, and severity of renal disease. Seventy percent of 23 patients with renal disease had immunofluorescent-positive findings of skin biopsies while 67% of six patients without renal disease had positive findings of skin biopsies. Three of five patients with renal biopsy-proven diffuse proliferative glomerulonephritis had positive findings of skin biopsies (60%), as did two of three patients with focal, proliferative glomerulonephritis and the single patient with membranous glomerulonephritis. There was no correlation between the presence of immune deposits on skin and the severity of the renal disease. There appears to be no correlation between the presence of the immunofluorescent skin test and the type or severity of renal disease in SLE.
Editorial board
Authors: James Field, Samuel Soskin, Beverly Hills, Garfield Duncan, Salman Azhar, Palo Alto, Hisham Barakat, George Bray, Jorge Calles-Escandon, Jose ´caro, M Charles, George Chrousos, Bernard Bethesda, St Davis, Leslie Louis, Frederick Degroot, Mario Derubertis, Atlanta Digirolamo, William Ga, Louis Duckworth, John Elsas, Kenneth Fain, San Feingold, Irving Francisco, Andrew Fox, New Frantz, Saul York, Henry Cleveland, New Ginsberg, Charles York, Jane Glueck, Abbas Cleveland, Fredric Kitabchi, Stanford Kraemer, Nelly Mauras, James May, Donald Mcnamara, Glenn Mortimore, Maria New, New York, Michael Pagliassotti, Ft Collins, William Pandak, Alan Richmond, Los Robinson, Stanton Angeles, Peter Segal, Richard Stacpoole, Marc Durham, John Tucson
Journal: Metabolism (2004)
Reply
Authors: J N Blackwell, D O Castell
Journal: Gut (1984)

Oesophageal chest pain SIR, -We would like to make three comments on the leading article by Drs Blackwell and Castell in the January issue of Gut. 1 They point the need for studies of oesophageal motility during effort angina in patients with proven coronary artery disease: we would refer them to our publications reporting that in six such patients we found no associated evidence of significant oesophageal dysmotility from simultaneous mano- metric studies. 3 They note the lack of controlled trials in the treatment of this condition: we would refer them to our preliminary report of a double blind, placebo controlled trial of nifedipine4 (a further paper in preparation).They comment on the dangers of ergometrine and the advantages of edrophonium.We find the ergo- metrine test useful3 5 6 and believe that it is safe, provided that patients are first carefully screened from the cardiological point of view and are shown not to have coronary artery disease, and that the oesophageal study is conducted with electrocardio- graphic monitoring and resuscitative facilities to hand, giving ergometrine in an initial dose of 0 05 mg, doubling every two to three minutes to a total of 0 5 mg over ca 10 minutes.We would point out that edrophonium is a cholinesterase inhibitor7 and that methacholine (a cholinergic agent and thus a vaso- constrictor) is capable of inducing coronary spasm in susceptible subjects8 9 so that the authors' suggestion that edrophonium is safer than ergo- metrine seems likely to represent a type II error.Because edrophonium has not yet been shown to induce coronary spasm does not mean that it does not.We would caution against accepting the view that edrophonium is safe on present evidence.
Gastrointestinal helminthiasis.
Authors: H. M. Gilles
Journal: BMJ (1968)

Most of the worms that affect man live unobtrusively in the gut and do little to impair the health of their host.Symptoms and signs usually only appear with heavy infections.Of the many intestinal worms likely to be brought into Britain by immigrants and travellers the ones most likely to be encountered by practitioners are hookworms, ascaris, strongyloides, whip- worms, and cestodes.Adult schistosomes live in the portal blood vessels, but since the ova of Schistosoma mansoni and S. japonioum are found in the faeces a short account of intes- tinal schistosomiasis will be given.
五种测量成人特应性皮炎严重程度的方法的比较
Authors: J.I. Silverberg, D.J. Margolis, M. Boguniewicz, L. Fonacier, M.H. Grayson, P.Y. Ong, Z.C. Fuxench, E.L. Simpson
Journal: British Journal of Dermatology (2020)

特应性皮炎 (AD) 也称为特应性湿疹, 是一种常见的皮肤疾病, 尤其在儿童中。 AD 可能导致多种可影响不同身体部位的皮肤病灶(湿疹斑块)以及不同程度的瘙痒和睡眠障碍。这些是 AD 严重程度的重要部分。 已经创建了许多不同的系统或“工具”来询问患者 AD 严重程度的这些方面的信息。这些工具可用于临床实践(即供医生和护士使用), 以确保患者获得正确的治疗。尚未明确其中一些工具的有效性(准确性)以及如何相互比较它们。 作者使用美国研究中的 AD 数据, 比较了 602 例美国成人 AD 患者对 6 个测量他们疾病严重程度的不同调查问卷的回答。 以患者为导向的湿疹测量 (POEM)、以患者为导向的 AD 评分 (PO‐SCORAD) 总分与客观和主观子评分, 以及数字评定量表 (NRS)‐瘙痒均可充分表明 AD 的严重程度。PO‐SCORAD 可很好地显示 AD 的严重程度以及对生活质量和心理健康的影响。 虽然这些工具存在一些有效性问题, 但作者认为它们足以评估 AD 在临床实践中的严重程度。 This summary relates to the study: 成人特应性皮炎严重程度的五种患者报告结果的验证
Public Health Reports, Washington
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial Board
Authors: Stavroula Kousta, Katja Brose, Rolf Van Der Sanden, Loek De Weerd, R Adolphs, R Baillargeon, N Chater, J Cohen, J Driver, A Engel, A Friederici, M Goodale, M Hauser, R Jackendoff, P Johnson-Laird, S Kosslyn, N Logothetis, J Mcclelland, L Nadel, S Pinker, T Robbins, S Shamma, A Wagner, V Walsh, D Wolpert, Diana Ong
Journal: Trends in Cognitive Sciences (2010)
Contents Vol. 28,1995
Authors: L Boccon-Gibod, Paris Debruyne, Nijmegen Fitzpatrick, Dublin Hohenfellner, Mainz Jimenez, S Karger, S Ebisuno, S Jahnson, B Risberg, M Karlsson, G Westman, R Bergström, J Pedersen, L Nava, P Pompa, M Grasso, P Rigatti, M Robinson, P Smith, B Richards, D Newling, M De Pauw, R Sylvester, G Cusumano, C Vicentini, P De Carli, L Ruco, A Santoni, A Cancrini, M Giuffrida, M Cippitelli, P Palmer, L Miano, E Moore, B Bracken, W Bremner, J Geller
Journal: European Urology (1995)
Acute Lymphoblastic Leukemia
Authors: Ching-Hon Pui, William E. Evans
Journal: New England Journal of Medicine (1998)

Acute lymphoblastic leukemia (ALL) is diagnosed in 3000 to 4000 persons in the United States each year; two thirds of them are children.1,2 The current rate of cure of nearly 80 percent in children attests to remarkable progress in the development of effective treatments for resistant subtypes of the disease. Progress has been incremental, from the introduction of combination chemotherapy and central nervous system treatment for presymptomatic leukemia to newer, intensive treatment regimens for patients at high risk for relapse (Figure 1). In contrast, only 30 to 40 percent of adults with ALL are cured.2,3 This discrepancy can . . .
Government Services
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
<i>Erratum:</i> Vol. 68, No. 16
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

in Figure 1, for Shiga toxin-producing Escherichia coli (STEC), the value for 2018 culture-independent diagnostic test (CIDT)-positive, culture-positive cases should have been 1,559, resulting in a total of 2,925 STEC cases in 2018, as seen in the Table on page 370. Culture-positive onlyCIDT-positive, culture-positive CIDT-positive, culture not done CIDT-positive, culture-negative
Medical Touts.
Authors: A. A. Marshall
Journal: JAMA (1897)

Marion, N. C., July 7, 1897. <h3>To the Editor:</h3> —Refer to yourJournalof July 3 issue, 1897, page 37, and advise me the name of the insurance society mentioned in the article headed " Life Insurance Fees for Medical Touts," or say if it is the—, and extremely oblige, Yours truly, <h3>Answer.</h3> —No reference to your company was intended by the editorial of July 3 on " Life Insurance Fees for Medical Touts." For obvious reasons, however, theJournalcan not give the name of the company whose offer was quoted. The offer itself is in the hands of the editorial staff and the quotation was<i>verbatim</i>.
Tonsillectomy
Authors: P. Scott
Journal: BMJ (1951)

Thyrotoxicosis remains a frustrating condition for the young person, family, and health professionals involved. The associated symptoms do not always suggest thyroid disease and patients can be unwell for many months before the diagnosis is made. The antithyroid drug regimen used to treat children and adolescents with thyrotoxicosis varies from one unit to another and yet the potentially life threatening side effects and remission rates post-treatment may be related to the regimen used. Most patients with thyrotoxicosis will need many years of drug therapy if the thyroid gland is not removed surgically or destroyed by radioiodine. Even “definitive” treatment will typically necessitate thyroxine replacement for life.